About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Global Biosimilars Market Size, Industry Worth USD 121.88 billion By 2033
Biosimilars Market

Biosimilars Market Size, Share & Trends Analysis Report By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Applications (Oncology, Blood Disorder, Growth Hormonal Disorders, Rheumatoid Arthritis, Chronic and Autoimmune Diseases), By Manufacturing Type (In-house manufacturing, Contract Manufacturing) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI544DR
Last Updated : January 23, 2025
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Biosimilars Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Recombinant Non-Glycosylated Proteins
        1. By Value
      3. Recombinant Glycosylated Proteins
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Blood Disorder
        1. By Value
      4. Growth Hormonal Disorders
        1. By Value
      5. Rheumatoid Arthritis
        1. By Value
      6. Chronic and Autoimmune Diseases
        1. By Value
    4. By Manufacturing Type
      1. Introduction
        1. Manufacturing Type By Value
      2. In-house manufacturing
        1. By Value
      3. Contract Manufacturing
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Recombinant Non-Glycosylated Proteins
        1. By Value
      3. Recombinant Glycosylated Proteins
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Blood Disorder
        1. By Value
      4. Growth Hormonal Disorders
        1. By Value
      5. Rheumatoid Arthritis
        1. By Value
      6. Chronic and Autoimmune Diseases
        1. By Value
    4. By Manufacturing Type
      1. Introduction
        1. Manufacturing Type By Value
      2. In-house manufacturing
        1. By Value
      3. Contract Manufacturing
        1. By Value
    5. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Recombinant Non-Glycosylated Proteins
          1. By Value
        3. Recombinant Glycosylated Proteins
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Blood Disorder
          1. By Value
        4. Growth Hormonal Disorders
          1. By Value
        5. Rheumatoid Arthritis
          1. By Value
        6. Chronic and Autoimmune Diseases
          1. By Value
      3. By Manufacturing Type
        1. Introduction
          1. Manufacturing Type By Value
        2. In-house manufacturing
          1. By Value
        3. Contract Manufacturing
          1. By Value
    6. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Recombinant Non-Glycosylated Proteins
        1. By Value
      3. Recombinant Glycosylated Proteins
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Blood Disorder
        1. By Value
      4. Growth Hormonal Disorders
        1. By Value
      5. Rheumatoid Arthritis
        1. By Value
      6. Chronic and Autoimmune Diseases
        1. By Value
    4. By Manufacturing Type
      1. Introduction
        1. Manufacturing Type By Value
      2. In-house manufacturing
        1. By Value
      3. Contract Manufacturing
        1. By Value
    5. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Recombinant Non-Glycosylated Proteins
          1. By Value
        3. Recombinant Glycosylated Proteins
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Blood Disorder
          1. By Value
        4. Growth Hormonal Disorders
          1. By Value
        5. Rheumatoid Arthritis
          1. By Value
        6. Chronic and Autoimmune Diseases
          1. By Value
      3. By Manufacturing Type
        1. Introduction
          1. Manufacturing Type By Value
        2. In-house manufacturing
          1. By Value
        3. Contract Manufacturing
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Recombinant Non-Glycosylated Proteins
        1. By Value
      3. Recombinant Glycosylated Proteins
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Blood Disorder
        1. By Value
      4. Growth Hormonal Disorders
        1. By Value
      5. Rheumatoid Arthritis
        1. By Value
      6. Chronic and Autoimmune Diseases
        1. By Value
    4. By Manufacturing Type
      1. Introduction
        1. Manufacturing Type By Value
      2. In-house manufacturing
        1. By Value
      3. Contract Manufacturing
        1. By Value
    5. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Recombinant Non-Glycosylated Proteins
          1. By Value
        3. Recombinant Glycosylated Proteins
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Blood Disorder
          1. By Value
        4. Growth Hormonal Disorders
          1. By Value
        5. Rheumatoid Arthritis
          1. By Value
        6. Chronic and Autoimmune Diseases
          1. By Value
      3. By Manufacturing Type
        1. Introduction
          1. Manufacturing Type By Value
        2. In-house manufacturing
          1. By Value
        3. Contract Manufacturing
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Recombinant Non-Glycosylated Proteins
        1. By Value
      3. Recombinant Glycosylated Proteins
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Blood Disorder
        1. By Value
      4. Growth Hormonal Disorders
        1. By Value
      5. Rheumatoid Arthritis
        1. By Value
      6. Chronic and Autoimmune Diseases
        1. By Value
    4. By Manufacturing Type
      1. Introduction
        1. Manufacturing Type By Value
      2. In-house manufacturing
        1. By Value
      3. Contract Manufacturing
        1. By Value
    5. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Recombinant Non-Glycosylated Proteins
          1. By Value
        3. Recombinant Glycosylated Proteins
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Blood Disorder
          1. By Value
        4. Growth Hormonal Disorders
          1. By Value
        5. Rheumatoid Arthritis
          1. By Value
        6. Chronic and Autoimmune Diseases
          1. By Value
      3. By Manufacturing Type
        1. Introduction
          1. Manufacturing Type By Value
        2. In-house manufacturing
          1. By Value
        3. Contract Manufacturing
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. The rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Recombinant Non-Glycosylated Proteins
        1. By Value
      3. Recombinant Glycosylated Proteins
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Blood Disorder
        1. By Value
      4. Growth Hormonal Disorders
        1. By Value
      5. Rheumatoid Arthritis
        1. By Value
      6. Chronic and Autoimmune Diseases
        1. By Value
    4. By Manufacturing Type
      1. Introduction
        1. Manufacturing Type By Value
      2. In-house manufacturing
        1. By Value
      3. Contract Manufacturing
        1. By Value
    5. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Recombinant Non-Glycosylated Proteins
          1. By Value
        3. Recombinant Glycosylated Proteins
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Blood Disorder
          1. By Value
        4. Growth Hormonal Disorders
          1. By Value
        5. Rheumatoid Arthritis
          1. By Value
        6. Chronic and Autoimmune Diseases
          1. By Value
      3. By Manufacturing Type
        1. Introduction
          1. Manufacturing Type By Value
        2. In-house manufacturing
          1. By Value
        3. Contract Manufacturing
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Biosimilars Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Pfizer, Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Novartis AG
    3. Biocon Ltd.
    4. TEVA Pharmaceutical Industries Ltd.
    5. Celltrion Pharma
    6. Amgen, Inc.
    7. Biocon
    8. Mylan N.V.
    9. Dr. Reddys Laboratories Ltd
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global biostimulants market size is projected to reach USD 7,879 million by 2030, from USD 2,897 million in 2021, and is anticipated to register a CAGR of 11.76% between 2022 and 2030. Biostimulants are natural or synthetic compounds that ca
Buy Now
Global Report
Market Overview The global oncology biosimilar market size was valued at USD 2.92 billion in 2022. It is projected to reach USD 15.62 billion by 2031, growing at a CAGR of 20.5% during the forecast period (2023-2031). Factors such as
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.